12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation

Sofosbuvir (SOF) combined with NS5A inhibitors has demonstrated its efficacy in treating a recurrence of HCV after liver transplantation. However, the duration of treatment and the need for ribavirin (RBV) remain unclear in this population. Our aim was to determine whether liver transplant recipient...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology (Baltimore, Md.) Md.), 2018-04, Vol.68 (4), p.1277-1287
Hauptverfasser:	Houssel-Debry, Pauline, Coilly, Audrey, Fougerou-Leurent, Claire, Jezequel, Caroline, Duvoux, Christophe, de Ledinghen, Victor, Radenne, Sylvie, Kamar, Nassim, Leroy, Vincent, Di Martino, Vincent, d'Alteroche, Louis, Canva, Valérie, Conti, Filomena, Dumortier, Jerome, Montialoux, Hélène, Lebray, Pascal, Botta-Fridlund, Danielle, Tran, Albert, Moreno, Christophe, Silvain, Christine, Besch, Camille, Perre, Philippe, Francoz, Claire, Abergel, Armando, Habersetzer, François, Debette-Gratien, Maryline, Cagnot, Carole, Diallo, Alpha, Chevaliez, Stéphane, Rossignol, Emilie, Veislinger, Aurelie, Duclos-Vallee, Jean-Charles, Pageaux, Georges-Philippe
Format:	Artikel
Sprache:	eng
Schlagworte:	Life Sciences
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Sofosbuvir (SOF) combined with NS5A inhibitors has demonstrated its efficacy in treating a recurrence of HCV after liver transplantation. However, the duration of treatment and the need for ribavirin (RBV) remain unclear in this population. Our aim was to determine whether liver transplant recipients could be treated with an SOF+NS5A inhibitor-based regimen without RBV for 12 weeks after liver transplantation (LT).
ISSN:	0270-9139 1527-3350
DOI:	10.1002/hep.29918